Premium
AEBP1, a prognostic indicator, promotes colon adenocarcinoma cell growth and metastasis through the NF‐κB pathway
Author(s) -
Xing Yanwei,
Zhang Zhiqiang,
Chi Fengxu,
Zhou Yang,
Ren Shuo,
Zhao Zhiwei,
Zhu Yuekun,
Piao Daxun
Publication year - 2019
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.23066
Subject(s) - cancer research , biology , vimentin , gene silencing , carcinogenesis , cell growth , adenocarcinoma , colorectal cancer , metastasis , cancer , medicine , oncology , immunology , immunohistochemistry , gene , biochemistry , genetics
Abstract The abnormal expression of adipocyte enhancer binding protein 1 (AEBP1) has been implicated in the carcinogenesis and progression of various types of human tumors. However, the role of AEBP1 in colon adenocarcinoma (COAD) remains largely unelucidated. In this study, we explored the clinical significance and biological function of AEBP1 in COAD. We observed that AEBP1 was overexpressed in COAD tissues and cells and that the expression of AEBP1 was correlated with tumor size, the level of histologic differentiation, lymph node metastasis, and cancer stage in COAD patients. In addition, univariate and multivariate Cox regression analyses revealed that high AEBP1 expression suggested poor prognosis in COAD. Moreover, AEBP1 silencing suppressed COAD cell proliferation, migration, and invasion, whereas the upregulation of AEBP1 promoted these behaviors. Additionally, mechanistic studies further demonstrated that AEBP1 promoted COAD cell proliferation, migration, and invasion by upregulating the expression of matrix metalloproteinase‐2, vimentin, and TWIST whereas downregulating that of E‐cadherin through the nuclear factor‐κB pathway. Collectively, these data indicated that AEBP1 may be a new prognostic factor and a potential gene therapy target in COAD.